KURA ONCOLOGY INC (KURA)

Sector: Health Care

    Home/Companies/KURA/Annual Meeting

2026 Annual Meeting Analysis

KURA ONCOLOGY INC · Meeting: June 4, 2026

Policy v1.2high confidenceView Filing ↗
For informational purposes only. This AI-generated analysis applies a published voting policy to publicly available proxy filings. It does not constitute investment advice, proxy voting advice, or a solicitation of any kind. AI analysis may be incomplete or inaccurate — always review the actual filing and make your own independent decision.

Directors FOR

1

Directors AGAINST

2

Say on Pay

FOR

Auditor

FOR

Director Elections

Election of Directors

1 FOR/2 AGAINST

Against Analysis

✗ AGAINST
Diane Parks3-year TSR trigger: KURA -27.4% vs peer median +94.2%, gap of -121.6pp exceeds 20pp threshold for negative absolute TSR5-year TSR confirms sustained underperformance: KURA -69.7% vs peer median +43.3%, gap of -113.0pp exceeds 20pp thresholdDirector tenure since October 2019 — fully overlaps the underperformance period

Ms. Parks has served since October 2019, fully overlapping the period in which Kura's stock fell 27.4% over three years while the company's own peer group rose 94.2% on average — a gap of 121.6 percentage points, far exceeding the 20-point threshold; the five-year record is equally poor (-69.7% vs. peer median +43.3%), confirming this is sustained underperformance rather than a temporary trough, so no mitigant applies.

✗ AGAINST
Mary T. Szela3-year TSR trigger: KURA -27.4% vs peer median +94.2%, gap of -121.6pp exceeds 20pp threshold for negative absolute TSR5-year TSR confirms sustained underperformance: KURA -69.7% vs peer median +43.3%, gap of -113.0pp exceeds 20pp thresholdDirector tenure since November 2018 — fully overlaps the underperformance period

Ms. Szela has served since November 2018, fully overlapping the underperformance period; Kura's stock declined 27.4% over three years against a peer group that gained 94.2% on average, and the five-year picture is worse (-69.7% vs. peer median +43.3%), ruling out any 5-year mitigant, so the TSR trigger fires without relief.

For Analysis

✓ FOR
Michael J. Vasconcelles, M.D.Director joined September 2024 — within the 24-month new-director exemption window

Dr. Vasconcelles joined the board in September 2024, which is less than 24 months before the 2026 annual meeting, making him exempt from the TSR underperformance trigger under the policy's new-director exemption; he also brings relevant oncology drug development expertise appropriate for a clinical-stage biopharmaceutical company.

Of the three Class III nominees, two (Parks and Szela) receive AGAINST votes because Kura's stock has dramatically underperformed its own compensation peer group over both three and five years — the stock is down 27% over three years while peers gained 94% on average, and down 70% over five years while peers gained 43% — and both directors have served long enough to be fully accountable for that record. The third nominee, Dr. Vasconcelles, is exempt because he joined the board less than 24 months ago.

Say on Pay

✓ FOR

CEO

Troy E. Wilson, Ph.D., J.D.

Total Comp

$4,735,016

Prior Support

N/A

The CEO's total compensation of $4,735,016 is within a reasonable range for a CEO at a biotech company of Kura's size (approximately $766M market cap) that achieved its first FDA approval and commercial launch in 2025 — a transformative milestone that justifies above-target incentive payouts. The pay mix is heavily weighted toward variable compensation (stock options represent the largest component, bonuses were tied to specific clinical, regulatory, and commercial milestones that were actually achieved), and the company maintains a meaningful clawback policy covering both misconduct and accounting restatements. While the stock has underperformed the XBI — SPDR S&P Biotech ETF over three years, the FDA approval of KOMZIFTI in November 2025 and the subsequent commercial launch represent tangible value-creating outcomes that align the above-target bonus payout with real corporate achievement rather than pay disconnected from results.

Auditor Ratification

✓ FOR

Auditor

Ernst & Young LLP

Tenure

N/A

Audit Fees

$1,341,089

Non-Audit Fees

$0

Ernst & Young charged $1,341,089 in audit fees for 2025 with zero non-audit, audit-related, tax, or other fees, meaning the non-audit fee ratio is 0% — well below the 50% threshold that would raise independence concerns; auditor tenure is not disclosed in the proxy so the tenure trigger cannot fire, and no material financial restatements were identified.

Overall Assessment

The 2026 Kura Oncology annual meeting presents a mixed ballot: two of three director nominees (Parks and Szela) receive AGAINST votes due to sustained, severe stock underperformance against the company's own peer group over both three and five years, while the third nominee (Vasconcelles) is exempt as a recent addition; the auditor ratification and say-on-pay proposals both pass cleanly, as Ernst & Young charges no non-audit fees and the CEO's pay program is reasonably structured around a genuinely transformative year that included Kura's first FDA approval and commercial product launch.

Filing date: April 10, 2026·Policy v1.2·high confidence

Compensation Peer Group

18 companies disclosed in 2026 proxy filing

RCUSArcus Biosciences
ARVNArvinas
COGTCogent Biosciences
CRNXCrinetics Pharmaceuticals
DAWNDay One Biopharmaceuticals
IDYAIDEAYA Biosciences
IOVAIovance Biotherapeutics
ITOSiTeos Therapeutics
JANXJanux Therapeutics
KYMRKymera Therapeutics
NUVLNuvalent
RLAYRelay Therapeutics
RVMDRevolution Medicines
SWTXSpringWorks Therapeutics
GPCRStructure Therapeutics
SMMTSummit Therapeutics
SNDXSyndax Pharmaceuticals
XNCRXencor